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Introduction: Esophageal endoscopic ultrasound-guided fine nee-
dle aspiration (EUS-FNA) is a minimally invasive staging procedure
for mediastinal lymph nodes in patients diagnosed with lung cancer.
But, a substantial false negative rate necessitates that patients re-
turning a negative EUS-FNA result must undergo a subsequent
surgical staging procedure. This study incorporates a fiberoptic
reflectance spectroscopy device into the EUS-FNA procedure to
asses the vascular physiology within the sampled lymph node. The
aims of this pilot study were to determine the feasibility of incorporat-
ing a reflectance spectroscopy device into the EUS-FNA clinical pro-
cedure and to gather preliminary information about the vascular phys-
iology within the center of normal and metastatic lymph nodes.
Methods: This study included 10 patients with proven or suspected
lung cancer and an indication for EUS-FNA. The procedure was
performed on seven normal (unenlarged, positron emission tomog-
raphy negative) nodes and seven suspicious (enlarged, positron
emission tomography positive), with the malignant status of all
nodes cytologically confirmed. Reflectance spectra were acquired
using a single optical fiber that fits through the end of the EUS-FNA
biopsy needle, with an outer fiber diameter of 0.38 mm.
Results: The procedure was successfully performed and did not
introduce complications. Model-based analysis of single fiber re-
flectance spectra provided quantitative information about the vascu-
lar physiology within the sampled lymph node. We observed that
metastatic lymph nodes were characterized by lower microvascular
oxygen saturation (50% versus 84%, p  0.01) and lower blood
volume fraction (5.6% versus 13.5%, p  0.01) than normal nodes.
Conclusions: Single fiber reflectance spectroscopy has the potential
to detect abnormal lymph node physiology.
Key Words: Lung cancer, Staging, Spectroscopy, Endoscopic ul-
trasound with fine needle aspiration, Hemoglobin saturation, Blood
volume fraction.
(J Thorac Oncol. 2010;5: 981–987)
For patients diagnosed with lung cancer, treatment optionsare dependent on the presence of metastatic cancer in the
mediastinal lymph nodes.1 In the absence of clearly identifi-
able distant metastases, imaging modalities such as computed
tomography (CT) and positron emission tomography (PET)
are used to identify suspicious nodes (based on size and
metabolic activity); however, the sensitivity and specificity of
these techniques are not sufficient to properly diagnose the
presence of metastatic cancer, and tissue acquisition from an
enlarged lymph node is needed for definitive confirmation.2,3
The gold standard procedure for mediastinal staging is an
invasive surgical biopsy of the lymph node, termed medias-
tinoscopy.4,5 An alternative staging approach uses endoscopic
ultrasound techniques that are introduced through the esoph-
agus or through the bronchial tree.6 These techniques provide
echo visualization of lymph nodes and allow incorporation of
fine needle aspirations (FNA) for minimally invasive tissue
acquisition. For staging of mediastinal lymph nodes, the
EUS-FNA (endoscopic ultrasound-guided FNA) procedure is
considered less invasive, less expensive, and less likely to
introduce complications than surgical staging procedures.6–12
However, EUS-FNA has a large false negative (FN) rate
(17–22%) compared with mediastinoscopy4,5,7–12: a sub-
stantial limitation that is attributed to localized malignant
areas within the node that were not sampled during EUS-
FNA tissue acquisition. The EUS-FNA FN rate is not reduced
substantially by increasing the number of aspirations from the
current standard (reasonable accuracy is obtained after ap-
proximately 313), and the inclusion of on-site cytopathology
may not only improve sensitivity9 but also introduces addi-
tional practical and economic considerations. Because of the
substantial EUS-FNA FN rate, the clinical guidelines recom-
mend that patients receiving a negative cytology result from
EUS-FNA biopsy of suspicious nodes must undergo a sub-
sequent surgical staging procedure for definitive confirmation
of the diagnosis4,5: a procedure that is (retrospectively) un-
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necessary in approximately 77 to 81% of patients, because
the negative EUS-FNA result was indeed correct. Hypothet-
ically, a method that provided additional, complementary
information about the malignant status of lymph nodes could
improve EUS-FNA FN rate, reducing unnecessary spending
of resources and avoiding unnecessary delay before the onset
of treatment administration.
Previous studies investigating the physiology of lymph
node metastases have observed systematic effects of the
metastatic sites on the vasculature within the node.14–18 These
studies observed the presence of aberrant vessels, displace-
ment of vessels, and avascular areas in the center of the
node, with the primary source of perfusion from the
peripheral vasculature. Such observations indicate a com-
promised vascular network within the center of the node,
changes that would affect local tissue blood content and
blood oxygen saturation. These physiologic changes pro-
vide a hypothetical basis to differentiate between normal
and metastatic lymph nodes; specifically, these physiolog-
ical aspects (microvascular saturation and blood content)
can be measured by fiberoptic reflectance spectroscopy.
This pilot study aims to incorporate a fiberoptic measure-
ment technique into the EUS-FNA procedure that would
return unique quantitative information about node vascular
physiology, information that would be complementary to
the cytologic observations, and potentially improve the
EUS-FNA FN rate.
Reflectance spectroscopy in the visible-near infrared
wavelength region provides information about the wave-
length-dependent optical properties that allow estimation of
tissue physiological parameters.19 The dominant absorption
bands of hemoglobin in the visible wavelength region allow
both the blood content and hemoglobin saturation to be
estimated from the reflectance measurement. Previously, our
group developed differential path-length spectroscopy (DPS)
to quantitatively determine tissue physiological characteris-
tics.20 DPS uses a unique probe geometry that provides
knowledge of the photon path length21 and allows accurate
description of optical properties in small volumes of tissue;
the accuracy of this technique has been extensively validated22
and clinically investigated.23–27 However, DPS probes in-
clude multiple optical fibers and are too large to be incorpo-
rated into the biopsy needle at the end of the EUS-FNA
catheter (which has an internal diameter of 0.45 mm). This
clinical application requires the use of a fiberoptic probe with
an outer fiber diameter (0.4 mm) that could be incorporated
into the narrow channel of the EUS-FNA device. Our group
has addressed this problem by developing a novel quantita-
tive analysis technique for reflectance spectra measured by a
probe that uses a single optical fiber to deliver and collect
light during the measurement28,29; these studies presented a
mathematical model of the single fiber (SF) photon path
length that is accurate over a wide range of optical properties
and allows quantitative analysis of SF reflectance spectra.
Recently,30 we described the detailed technical aspects asso-
ciated with incorporating SF reflectance probes into the
EUS-FNA procedure for mediastinal lymph node staging:
aspects that included the characterization of the chro-
mophores (absorbing compounds) present within lymph node
tissue, the development of a mathematical model of SF
reflectance spectra measured within the lymph node in vivo,
and a detailed analysis of the effects of probe pressure on the
measured spectra. In this work, we describe the clinical
aspects of a pilot study that incorporated SF reflectance
spectroscopy into EUS-FNA staging of mediastinal lymph
nodes and present a novel optical sampling strategy that
addresses the sampling error associated with the current
EUS-FNA biopsy technique. The specific aims of this pilot
study are to show the feasibility of conducting the technique
in a clinical setting and to gather preliminary information
about the vascular physiology within the center of normal
(nonsuspicious) and metastatic (suspicious) lymph nodes in
patients undergoing EUS-FNA.
METHODS
Subjects
The Medical Ethics Committee of the Erasmus Medical
Centre (Rotterdam, The Netherlands) approved this observa-
tional study. Patients were recruited from the Erasmus Med-
ical Centre and from the Amphia Hospital (Breda, The
Netherlands) between December 2008 and April 2009. Pa-
tients who had an indication for an EUS-FNA procedure (i.e.,
presented enlarged lymph nodes on CT scan, or positive
lymph nodes on a PET scan, or had a primary tumor or had
an enlarged left adrenal gland that was reachable by EUS-
FNA) were asked to participate. According to published
guidelines for mediastinal staging,4,5 all reachable nodes were
sampled with FNA to optimally stage the mediastinum; not
all FNA sampled lymph nodes were measured by reflectance
spectroscopy. Written informed consent to perform the pro-
cedure was obtained from all patients before inclusion.
Classification of Lymph Nodes
In this study, both unenlarged nonsuspicious (normal)
lymph nodes and enlarged suspicious lymph nodes containing
metastatic cancer were included (throughout this article,
lymph nodes containing metastatic cancer are referred to as
metastatic). Suspicious lymph nodes were defined as visible
on CT-scan with a short-axis diameter of more than 10 mm
and were PET positive. Nonsuspicious (normal) lymph nodes
were defined as PET negative with a short-axis diameter of
less than 10. This pilot study included only nodes with a very
defined clinical suspicion for a diagnosis and, therefore,
excluded PET negative lymph nodes with short-axis diameter
of more than 10 mm. The classification of each node was
confirmed by cytology. Normal nodes were observed during
minimal 6-month follow-up examinations (except in one who
underwent surgical staging) to confirm no suspicious enlarge-
ment of the node had occurred.
Single Fiber Reflectance Device
SF reflectance spectra were measured using a custom-
made instrument shown in Figure 1. The SF probe contained
a single optical fiber for both light delivery and light collec-
tion and was small enough (outer diameter of 0.38 mm) to be
fed through the biopsy needle channel of the EUS-FNA. The
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proximal end of the SF probe connects to a bifurcated fiber,
with one arm leading to a tungsten-halogen lamp (HL-2000-
FHSA; Ocean Optics, Duiven, The Netherlands) and the
other arm leading to a spectrophotometer (SD 2000; Ocean
Optics). The distal end of the SF probe, which is in contact
with the tissue during measurement, is polished at an angle of
15 degrees to minimize the collection of specular reflection
that is caused by refractive index mismatch between the fiber
and tissue. During measurement, light in the visible-near
infrared wavelength range (400–900 nm) travels from the
lamp to the SF probe tip, exits the fiber, and scatters through-
out the tissue. Light that is remitted from the tissue and is
collected by the fiber returns a wavelength-dependent reflec-
tance intensity (RSF). A calibration procedure was described
previously28 to account for internal reflections and for vari-
ability in lamp-specific output and in fiber-specific transmis-
sion characteristics.
Examination Procedure
EUS-FNA procedures were performed in an outpatient
setting with monitoring of heart rate and oxygen saturation.
Lidocaine gel was orally administered (10 ml) before the
EUS-FNA procedure to provide local throat and esophageal
anesthesia. The patient was oriented into left lateral decubi-
tus, and midazolam was intravenously administered (2.5–5.0
mg) for mild sedation before introduction of the endoscope
(Olympus GF-UCT160-OL5). On placement of the endo-
scope within the esophagus in proximity to the targeted
lymph node, a sterile single-use needle (Cook Echo-1-22)
was introduced through the esophagus and into the lymph
node using echo guidance. After needle placement, the guide
wire was removed from the needle channel, and a sterilized
single-use SF probe was introduced into the FNA channel.
The fiberoptic probe was extended approximately 3 mm
through the EUS-FNA needle into the center of the lymph
node and allowed to rest with no external pressure applied to
the probe during spectral acquisition. Manipulation of the
probe to different locations within the node during measure-
ment can exert pressure-induced changes to the endogenous
physiology within the node,30 a confounding factor that is
avoided using the current sampling strategy of a limited
number of SF measurement sites near the center of the node.
Multiple spectral acquisitions were performed with a speci-
fied minimum of three measurements and additional measure-
ments obtained based on the judgment of the clinician con-
ducting the procedure (range: 3–11, average 7). After
reflectance measurements, the fiberoptic probe was removed
and the routine FNA performed to obtain cytologic aspira-
tions. In this study, 1 to 2 lymph nodes per patient were
measured with SF reflectance spectroscopy during each
EUS-FNA procedure; a new FNA needle and a new fiber-
optic probe were used for each node sampled to avoid
blood and tissue contamination between nodes. On aver-
age, each EUS-FNA procedure lasted 30 minutes. After the
FIGURE 1. Setup used for optical
measurements made during EUS-
FNA staging of mediastinal lymph
nodes. This measurement uses a
single optical fiber to deliver white
light to the lymph tissue in vivo
and deliver light remitted from tis-
sue and collected by fiber to the
spectrophotometer. EUS-FNA, en-
doscopic ultrasound-guided fine
needle aspiration.
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procedure, patients were observed for 1 hour and then
visited by the endoscopist to reveal any side effects. Three
days after the procedure, all patients were returned for an
outpatient visit to receive test results and to reveal any
further side effects.
Mathematical Analysis of Spectra
SF reflectance spectra (RSF) were analyzed using a
previously developed27 mathematical model that describes
the wavelength-dependent effects of scattering and absorp-
tion on the reflectance intensity collected by the SF device in
lymph node tissue. The model is given as follows
RSF a10
a2eatissueLSF (1)
Here, the term in square brackets is a background
scattering model that follows Mie theory dependence, with
fitted parameters describing the Mie amplitude (a1) and Mie
slope (a2); Rayleigh scattering was shown not to contribute to
RSF measured in lymph node tissue.30
The model describes attenuation because of absorption
through the modified Beer-Lambert law that includes the
product of the absorption coefficient within the lymph node
tissue a
tissue) and the SF photon path length LSF). Our
previous study,30 described the basis set of chromophores
within lymph tissue as oxygenated and deoxygenated hemo-
globin (HbO2 and Hb, respectively) and albumin-bound bil-
irubin. The summed contribution of each of these compo-
nents to a
tissue is given as follows
a
tissue CvSt02a
HbO2 1 St02a
Hba
bilirubinCbilirubin
(2)
Here  is the blood volume fraction, StO2 is the micro-
vascular saturation, a
HbO2 is the specific absorption coefficient
of oxygenated hemoglobin, a
Hb is the specific absorption
coefficient of deoxygenated hemoglobin, and a
bilirubin and
Cbilirubin are the specific absorption coefficient and concentra-
tion of albumin-bound bilirubin, respectively. Within tissue,
whole blood (and in turn Hb and HbO2) is located within the
vasculature. This heterogeneous distribution affects the spec-
tral shape of the absorption detected by reflectance spectros-
copy: an effect that is characterized by the Cv term,31 which
is given as Cv 	 {1  expa
bloodDv}/{a
bloodDv}, and in-
cludes an estimate of the average vessel diameter Dv.
Application of the Beer-Lambert law in Equation 1 requires
knowledge of LSF, a factor that is complicated by the
dependence of the collected photon paths on both the absorp-
tion and scattering properties within the optically sampled
tissue volume. Recently,28,29 our group developed an empir-
ical model that accurately describes LSF in terms of the SF
diameter dfiber, reduced scattering coefficient s
, and ab-
sorption coefficient a
 and is given as follows
LSF
1.54dfiber
(dfibers
)
0.18 0.61 dfibera
0.61
(3)
Fitting the measured RSF data with the model given in
Equation 1 yielded estimates for the microvascular saturation
(StO2), blood volume fraction (), average vessel diameter Dv,
bilirubin concentration C bilirubin, and Mie slope (a2); the scat-
tering amplitude (a1) did not provide unique information be-
cause of differences in calibration procedure between probes.30
Statistical Analysis
The difference of SF-estimated physiological parame-
ters between normal and metastatic lymph nodes was evalu-
ated with a Kruskal-Wallis test. This nonparametric test was
selected because of the small number of data points. The
values of P less than 0.05 were regarded as significant.
Spectra that showed evidence of a blood pool within the
detection volume were identified as  more than 40% and not
included in the statistical analysis.
RESULTS
Lymph Node Staging
Ten patients were included (six men and four women)
with an average age of 68 (11.8) years. Spectroscopic
measurements took place in 14 lymph nodes that were clas-
sified before the EUS-FNA based on CT and PET scans and
subsequently confirmed through cytology (seven normal and
seven metastatic). Cytologic conclusions of the metastatic
lymph nodes were two adenocarcinomas, one undifferenti-
ated large cell carcinoma (large cell), and four small cell
carcinomas. Table 1 includes a detailed breakdown of pa-
tient-specific factors for each sampled lymph node.
Tolerance of the EUS-FNA with combined SF mea-
surements was excellent in all patients, and no adverse events
of the spectroscopy procedure were observed; addition of SF
measurements extended no procedure by longer than 5 min-
utes. During the procedure, reflectance spectra and extracted
physiological parameter estimates were visible less than 1
second after each measurement, information that would im-
mediately indicate if the probe tip was located in a blood
pool, necessitating repositioning of the probe and measure-
ment of additional spectra. This was the case in two normal
nodes and one metastatic node.
Single Fiber Reflectance Spectra
Figure 2 displays representative SF reflectance spectra
collected from measurements of a metastatic (top) and a normal
(bottom) lymph node, both from a single patient (patient 9,
nodes 12 and 13 from Table 1). The plots show measured data
points, and the line represents the model fit from Equation 1. The
absorption bands of hemoglobin are visible in the spectra as the
dips between 500 and 600 nm; the magnitude and shape of these
spectral features inform model estimates of blood volume frac-
tion () and microvascular saturation (StO2). Table 1 includes a
summary of  and StO2 estimates for each lymph node sampled
by SF, with SDs calculated from multiple spectra measured
within each node.
Inspection of these data show that metastatic lymph
nodes are associated with lower StO2 (50% versus 84%) and
lower  (5.6% versus 13.5%) than normal nodes; comparison
of the mean values of these parameters between normal and
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metastatic nodes indicates significant differences (p  0.01
for each). Although other optical parameters (specifically, Dv,
Cbilirubin, and a2) extracted from SF spectra showed differ-
ences in the mean between normal and metastatic nodes,
these differences were not significant and are not presented in
detail in this article.
DISCUSSION
This work presents the first clinical pilot study incor-
porating SF reflectance spectroscopy into the EUS-FNA pro-
cedure for staging of mediastinal lymph nodes. The incorpo-
ration of the SF technique was feasible, quickly performed in
the clinical setting, and did not introduce complications or
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FIGURE 2. Single fiber reflectance
spectra and model fit as measured
in metastatic (top) and normal
(bottom) lymph nodes within the
same patient (patient 9, nodes 12
and 13 in Table 1). Spectra are
shifted on horizontal axis for clarity
(arbitrary units). These spectra
show differences in both the oxy-
genation (StO2) and volume frac-
tion () of blood.
TABLE 1. Characteristics of Patients and Lymph Nodes Included in this Pilot Study
Patient Node Gender Age (yr) Site Diameter (mm) PET Classification Cytology EUS Use
StO2 (%)  (%)
Mean SD Mean SD
1 1 F 48 LN 7 40–20 Positive M Adenocarcinoma Staging 10.8 5.0 1.6 0.5
2 2 M 53 LN 7 15–0.8 Negative N Normal Staging 81.1 4.4 16.4 6.2
3 M 53 LN 4L 0.4–0.4 Negative N Normal Staging 79.3 0.8 15.3 1.4
3 4 M 82 LN 7 13–0.5 Negative N Normal Staging 91.4 0.6 8.4 1.9
5 M 82 LN 4 L 30–20 Positive M Large cell Staging 47.4 22.7 0.12 0.03
4 6 F 82 LN 5 0.7–2.3 Positive M Adenocarcinoma Staging 48.8 11.4 1.9 1.0
5 7 F 72 LN 4 L 1.4–1.8 Positive M SCLC Staging 34.2 14.1 5.8 1.9
6 8 M 63 LN 7 2.9–1.7 Positive M SCLC Staging 54.9 19.9 5.9 1.7
7 10 M 58 LN 7 3.2–1.3 Positive M SCLC Staging 87.7 11.7 6.6 2.9
8 11 M 76 LN 7 1.8–0.6 Negative N Normal Enlarged adrenal
gland
75.3 3.1 3.2 0.6
9 12 M 75 LN 7 1.8–0.3 Negative N Normal Staging 95.8 1.8 26.6 3.3
13 M 75 LN 4L 3.6–4 Positive M SCLC Staging 69.0 9.2 3.1 1.0
10 14 F 67 LN 7 1.5–0.1 Negative N Normal Primary tumor
puncture
69.9 4.5 8.7 0.8
15 F 67 LN 4L 1.8–0.2 Negative N Normal Primary tumor
puncture
94.4 3.2 16.1 3.2
Nodes were classified as normal (N) or metastatic (M). Note both normal and metastatic nodes were measured in patients 3 and 9. Patient 2 had a positive cytology for a lymph
node located at location LN 5/6, which was not measured by SF reflectance spectroscopy.
PET, positron emission tomography; EUS, endoscopic ultrasound; SCLC, small cell carcinoma.
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extend the procedure by more than 5 minutes. SF reflectance
spectra provided quantitative information about the tissue
physiology within the lymph nodes. We observed differences
in the mean values of the model estimates of microvascular
saturation and blood volume fraction between normal and
malignant nodes, with metastatic lymph nodes characterized
by a lower blood volume fraction and lower microvascular
saturation: observations that are associated with a compro-
mised vascular supply.
Previous studies have described the disruptive effect
that metastatic cancer within lymph nodes has the vascular
supply and perfusion within the node. During the develop-
ment of metastatic sites within lymph nodes, malignant cells
invade the node through the afferent lymphatic vessels and
then enter the subscapular sinus and cortex of the node, an
infiltration route that usually results in metastatic sites located
in the peripheral areas of the node.15,32 As these metastatic
sites proliferate and locally upregulate angiogenesis, they
increase the vascularity in the peripheral areas of the
node.14,15,33,34 These morphologic changes exert a mechanical
(hydrostatic) pressure on the center of the node, compromis-
ing the central blood supply. Larger metastases destroy or
displace the regular vascular network throughout the center of
the lymph node, a feature that can be exacerbated by central
necrosis or keratinization within the node.16,17 It is not well
known if these changes are tumor-type specific or if these
changes are representative of metastatic infiltration from all
tumor types. Previous studies using Doppler techniques re-
ported abnormal vascular characteristics of metastatic nodes,
including the presence of aberrant vessels, displacement of
vessels, and avascular areas, with the primary source of
perfusion from the peripheral vasculature.14,16–18,33,34 Our
fiberoptic measurements estimated a reduction in blood vol-
ume fraction and microvascular saturation in the center of
metastatic nodes as compared with normal nodes, observa-
tions that are consistent with the previous descriptions in the
literature of vascular physiology within metastatic lymph
nodes. These observations support the concept that reflec-
tance spectroscopy can detect abnormal vascular physiology
associated with metastatic lymph nodes.
For EUS-FNA staging of lung cancer patients, the
clinically relevant problem is the classification of suspicious
nodes as either reactive (benign) or metastatic. Lymph nodes
undergoing a reactive immune response may appear suspi-
ciously enlarged on CT and/or show increased activity on
PET.35 These reactive nodes are known to present vessel
dilation and hypervascularity with the highest perfusion in the
center of the node and proportionality between perfusion and
volume of the enlarged nodes36: factors that would result in
an increase in blood volume fraction while maintaining a high
microvascular saturation within the node. Doppler techniques
have been used to qualitatively observe and distinguish be-
tween increased perfusion within reactive nodes36,37 and
decreased perfusion within the center of metastatic
nodes14,33,34; such differences in the vascular networks are
expected to translate into differences in physiology that are
quantitatable by SF reflectance measurements. Moreover,
these findings suggest that differences in vascular character-
istics between reactive and metastatic nodes are more pro-
nounced than what was observed between normal and meta-
static nodes in this study. These factors suggest that only a
limited number of SF reflectance measurements made near
the center of a node would be required to quantify the
regional effect of metastatic disease (or the regional effect of
benign infection) on the node physiology. Such a fiberoptic
sampling strategy specifically would not require optical sam-
pling of localized malignant areas within a node and, there-
fore, would directly address the sampling error associated
with the current EUS-FNA biopsy technique. It is important
to note that whereas the tumor load required to change node
physiology is currently unknown, the nodes undergoing sam-
pling within this scheme (will) have appeared enlarged on
imaging scans (or are PET positive) and, therefore, if the
tumor load is responsible for node enlargement or enhanced
metabolic activity, it is reasonable to assume that the node
physiology has been altered accordingly. Nevertheless, the
sensitivity of the SF reflectance measurement to changes in
vascular physiology associated with the size of the tumorload
within metastatic nodes should be carefully investigated in an
expanded clinically relevant data set.
Although the preliminary data presented in this study
are promising, this pilot study is limited in scope and requires
further clinical investigation. This pilot study included a
restricted patient population, with reflectance measurements
acquired only from nodes with a very defined clinical suspi-
cion for a diagnosis, normal (unenlarged, PET negative) and
metastatic (enlarged, PET positive), while excluding small
suspicious nodes (unenlarged, PET positive). This population
was selected to gather preliminary insight into the vascular
physiology associated with the limiting normal/metastatic
cases, and moreover, this strategy avoided the inclusion of
nodes enlarged because of immune reaction into the normal
designation used in this study. Future work will involve a
clinical investigation within a large population of patients
presenting suspicious nodes investigated by EUS-FNA. An-
other limitation of this pilot study was the determination of
normal nodes without surgical staging procedures to confirm the
absence of metastases. Instead, this study confirmed normal
nodes using cytologic analysis of aspirate acquired during EUS-
FNA and conducting subsequent follow-up examinations to
confirm that nodes identified as normal did not increase in
size. This methodology cannot conclusively rule out the
inclusion of a FN within the presented set of normal nodes.
Further investigation is required to make concrete conclu-
sions about the clinical utility of the vascular information
extracted from reflectance measurements of lymph nodes.
In conclusion, SF reflectance spectroscopy allows real-
time analysis of the vascular physiology in lymph nodes
undergoing EUS-FNA staging procedures. Incorporation of
the SF technique into the EUS-FNA was well tolerated and
simple to use, and the measured spectra provided unique
quantitative information about lymph node vasculature. The
SF reflectance technique has the potential to improve the
quantitative understanding of vascular physiology within
lymph nodes, understanding that has previously been based
on qualitative Doppler techniques. The data presented in this
study demonstrate the feasibility and potential utility of SF
measurements of vascular changes associated with the pres-
ence of metastases within lymph nodes. Moreover, the results
obtained within this pilot study support the rationale for a
novel fiberoptic sampling strategy during EUS-FNA, which
involves the detection of regional effects of metastatic sites
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on lymph node physiology: a sampling strategy that would
not require direct optical sampling of metastatic sites within
nodes. In addition, the SF technology is extensible to any
accessible lymph node and may provide information about
nodal vascular physiology during staging of mediastinal and
hilar lymph nodes through the bronchial tree.
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